Informational only. Not medical advice. Tesamorelin requires a prescription. CJC-1295 is not FDA-approved and is sold by gray-market vendors labeled "for research use only." Speak with a licensed clinician before any peptide decision.

Both are GHRH analogs. Both raise GH and IGF-1. That's where the similarity ends. The two split sharply on structure, evidence base, FDA status, and price. For broader context on the GHRH/secretagogue category, see our growth hormone peptides overview covering sermorelin, ipamorelin, and CJC-1295.

A 2026 meta-analysis of five RCTs found tesamorelin cut visceral fat by a mean of 27.71 cm² versus placebo (ScienceDirect, 2026). CJC-1295 has no comparable human data. That gap drives most of the differences below.

What is the difference between tesamorelin and CJC-1295?

Tesamorelin is a full 44-amino-acid synthetic GHRH analog with one N-terminal modification (FDA-approved as Egrifta for HIV-linked lipodystrophy). CJC-1295 is a modified GHRH 1-29 fragment with four amino acid substitutions, sold as a research chemical with no FDA approval. The DAC ("drug affinity complex") version of CJC-1295 binds serum albumin, extending its half-life to 6-8 days versus tesamorelin's 26 minutes (J Clin Endocrinol Metab, 2006).

Both bind the GHRH receptor on the pituitary. Tesamorelin produces pulsatile GH release similar to the natural rhythm; CJC-1295-DAC produces a sustained IGF-1 elevation lasting 9-11 days from a single dose. Whether sustained or pulsatile signaling is preferable for body composition has never been head-to-head trialed in humans.

Which is better for fat loss: tesamorelin or CJC-1295?

Tesamorelin — by a wide margin on evidence quality. CJC-1295 has zero published RCTs measuring fat loss as an outcome. A 2026 meta-analysis pooled five tesamorelin RCTs (n>1,400) and found a mean -27.71 cm² visceral fat reduction (95% CI -38.37 to -17.06; p<0.001) versus placebo (ScienceDirect, 2026). A 12-month Mass General trial found tesamorelin cut hepatic fat by ~32% vs no change in placebo in HIV patients with NAFLD (Lancet HIV, 2019).

CJC-1295's human evidence base is two short 2006 Phase I trials with <50 healthy adults total (J Clin Endocrinol Metab, 2006). Both measured drug levels and IGF-1. Neither measured belly fat, lean mass, or any body composition endpoint.

Claims that CJC-1295 produces "tesamorelin-like" fat loss rest on extrapolation from IGF-1 levels — not direct measurement.

Is CJC-1295 FDA-approved like tesamorelin?

No. Tesamorelin is FDA-approved for HIV-linked lipodystrophy (Egrifta SV in 2010, Egrifta WR in 2025). CJC-1295 has never been FDA-approved for any indication. The FDA placed CJC-1295 on the 503A "Category 2" list in 2023, preventing compounding pharmacies from producing it for routine use (ProPublica, 2025). In September 2024 the FDA pulled CJC-1295 from Category 2 and sent it for review — no final ruling as of May 2026.

Most U.S. CJC-1295 supply now comes from research-chemical vendors labeled "not for human use." That label does not protect the buyer. For an overview of the legal sourcing landscape, see our where to buy peptides legally guide.

How do tesamorelin and CJC-1295 actually compare across all 10 dimensions?

The table below summarizes structure, evidence, regulatory status, and cost. Per-row detail follows.

#	Dimension	Tesamorelin	CJC-1295	Winner
1	Peptide structure	Synthetic GHRH 1-44 (44 amino acids)	Modified GHRH 1-29 with 4 substitutions	Tied (different goals)
2	Half-life	~26 minutes	~30 min without DAC; 6-8 days with DAC	CJC-1295 with DAC
3	FDA status	Approved (Egrifta SV, Egrifta WR)	Not approved; was on 503A Category 2	Tesamorelin
4	Human RCT count	5+ RCTs, n>1,400 pooled	2 short Phase I trials, n<50	Tesamorelin
5	Visceral fat evidence	-27.71 cm² mean reduction vs placebo (meta)	None — no body comp endpoint trialed	Tesamorelin
6	Liver fat (NAFLD) evidence	-32% hepatic fat at 12 months	No published liver outcome data	Tesamorelin
7	Prescription path	Specialty pharmacy via HIV provider	Compounding pharmacy or research vendor	Tesamorelin (legal clarity)
8	2026 monthly cost	$2,400-$3,085 brand; $150-$300 compounded	$50-$300 gray market	Depends on legal preference
9	Insurance coverage	Yes, for HIV lipodystrophy	None	Tesamorelin
10	Safety profile	IGF-1 elevation, glucose intolerance (mapped)	One cardiac death in Phase II; injection-site reactions (sparse)	Tesamorelin (better characterized)

1. Peptide structure — tesamorelin is full-length GHRH; CJC-1295 is a modified fragment

Tesamorelin is a synthetic copy of the full 44-amino-acid human GHRH with a trans-3-hexenoic acid group at the N-terminus to slow breakdown (FDA label, 2019). CJC-1295 starts from the shorter GHRH 1-29 fragment and swaps amino acids at positions 2, 8, 15, and 27 to resist enzyme breakdown (Biotech Peptides, 2026). Both bind the GHRH receptor; the structure gap matters less than the half-life gap from the DAC add-on.

2. Half-life — CJC-1295 with DAC lasts days; tesamorelin clears in under an hour

Tesamorelin has a plasma half-life of ~26 minutes after injection (Drugs.com monograph, 2024). It produces a single GH pulse and clears. CJC-1295 with DAC binds serum albumin; its half-life jumps to 5.8-8.1 days, and IGF-1 stays elevated 9-11 days from one dose (J Clin Endocrinol Metab, 2006). Without DAC, "modified GRF 1-29" behaves more like tesamorelin. Most gray-market CJC-1295 sold today is the DAC version.

3. FDA status — only tesamorelin is approved for humans

Tesamorelin is FDA-approved as Egrifta SV (2010, with 2019 reformulation) and Egrifta WR (2025 weekly version). Both approvals are for HIV-linked lipodystrophy (Theratechnologies, 2025). CJC-1295 has no FDA approval. The 503A Category 2 placement in 2023 blocked compounding; the September 2024 removal sent it for further review with no final ruling.

4. RCT count — tesamorelin has 5+ trials; CJC-1295 has 2 short ones

A 2026 review found five RCTs of tesamorelin in HIV-linked lipodystrophy with pooled enrollment topping 1,400 patients (ScienceDirect, 2026). CJC-1295's human evidence base is two Phase I trials from 2006, each with fewer than 50 healthy adults, measuring drug levels over 28-49 days (J Clin Endocrinol Metab, 2006). No Phase II or III CJC-1295 trial exists in print.

5. Visceral fat — only tesamorelin has direct RCT proof

The 2026 meta-analysis found tesamorelin cut visceral fat by -27.71 cm² (95% CI -38.37 to -17.06; p<0.001) across five trials (ScienceDirect, 2026). A post hoc analysis of the Phase III trial confirmed belly fat reduction whether or not "buffalo hump" was present (PMC, 2020). CJC-1295 has no RCT that measured belly fat.

6. Liver fat — tesamorelin cut hepatic fat 32%; CJC-1295 has no liver data

Stanley and team at Mass General ran a 12-month trial of tesamorelin in HIV patients with NAFLD. Liver fat fell ~32% versus no change in placebo (Lancet HIV, 2019). A follow-up showed tesamorelin slowed liver fibrosis in the same group (JCI Insight, 2020). A Phase II trial of tesamorelin in non-HIV NAFLD is ongoing (ClinicalTrials.gov NCT03375788). CJC-1295 has no liver data in print.

7. Prescription path — tesamorelin has one; CJC-1295 does not

Tesamorelin is filled through specialty pharmacies on a script from an HIV doctor or endocrinologist. Off-label use for general body composition is legal but not paid by insurance. CJC-1295 has no real prescription path in the U.S. Most buyers source from research-chemical sites tagged "not for human consumption" — a label that does not protect the buyer.

8. Cost in 2026 — brand tesamorelin is 10-30x the cost of gray-market CJC-1295

Brand Egrifta SV runs $2,400-$2,800/month without insurance. Egrifta WR (weekly version) lists at $3,085/month (Better Results Book, 2026). Compounded tesamorelin from telehealth firms runs $150-$300/month (PrymaLab, 2026) — off-label and not paid by insurance. Gray-market CJC-1295 (often stacked with ipamorelin) runs $50-$300/month from research vendors. Low price reflects no pharmacy oversight, no sterility testing, no identity verification. For vendor-side considerations, see best peptide vendors ranked by third-party testing.

9. Insurance coverage — only brand tesamorelin gets paid

Insurance covers brand Egrifta SV and Egrifta WR for HIV-linked lipodystrophy when prior authorization is met (Molina Healthcare PA criteria, 2024). Theratechnologies runs a patient-assistance program that can cut co-pays to $0-$50 for qualified patients. Compounded tesamorelin for off-label body composition is not covered. CJC-1295 is never covered. For broader category context, see our peptide therapy side effects and risks guide.

10. Safety — tesamorelin's risks are mapped; CJC-1295's are not

In tesamorelin's main trials, 7.6% of treated patients had injection-site itch versus 0.8% on placebo. About 47% had IGF-1 levels above +2 SDS at 26 weeks. About 5% had an HbA1c rise (≥6.5%) versus 1% on placebo (FDA label, 2019). The label requires baseline and periodic glucose monitoring.

CJC-1295's safety profile rests on small Phase I data. A Phase II trial in 192 HIV patients had one cardiac death of undetermined cause; the trial did not finish and full results were never published (ProPublica, 2025). The FDA has flagged purity and immune-reaction risks for CJC-1295. Long-term human safety data does not exist.

Bottom line

For body composition with real human data, tesamorelin wins on every dimension that requires a trial: five RCTs, FDA approval, a mapped safety profile, insurance coverage for the approved use. CJC-1295 is cheaper and lasts longer in the body. Neither advantage offsets the lack of human data, the legal gray zone, or the unknown long-term risk profile. Anyone weighing either choice should work with a licensed clinician and source from a pharmacy that can verify identity, purity, and potency.

Frequently asked questions

Is CJC-1295 legal in the U.S. in 2026? CJC-1295 is not FDA-approved for human use. It was placed on the FDA's 503A Category 2 list in 2023 and sent for review in September 2024. As of May 2026, no final ruling has been issued (ProPublica, 2025). Most U.S. CJC-1295 sales are tagged "not for human use."

Why is brand tesamorelin so much pricier than CJC-1295? Brand Egrifta WR carries the costs of FDA approval, specialty pharmacy supply, and adverse-event reporting. Compounded tesamorelin drops to $150-$300/month. Gray-market CJC-1295 has none of these costs and none of the quality controls (PrymaLab, 2026).

Can tesamorelin be used for body composition outside HIV? Off-label use is legal but rare. Insurance only pays for the HIV lipodystrophy indication. A Phase II trial in non-HIV NAFLD is ongoing (ClinicalTrials.gov NCT03375788). Until that trial reports, off-label use rests on the HIV evidence base.

Does CJC-1295 raise IGF-1 more than tesamorelin? A single dose of CJC-1295 with DAC raises IGF-1 1.5-3x for 9-11 days (J Clin Endocrinol Metab, 2006). Tesamorelin's IGF-1 elevation is more pulse-like — ~47% of patients exceed +2 SDS at 26 weeks (FDA label, 2019). Long-term IGF-1 elevation risk is unknown for both.

Should I take CJC-1295 with or without DAC? This is a clinical decision that needs a doctor. The DAC version has a 6-8 day half-life and easy dosing but maintains elevated levels for days. The non-DAC version mimics natural GH pulses but requires many weekly injections. Neither is FDA-approved.

Researched and drafted by Theo Park, an AI editorial persona at Peptide Front, against published sources. Reviewed by our editorial team.

Tesamorelin vs CJC-1295: FDA Status, RCTs, Cost 2026

Quick Answer